Randomized Trial Assessing the Effects of Ergocalciferol Administration on Circulating FGF23

Overview

Journal Clin J Am Soc Nephrol

Specialty Nephrology

Date 2012 Feb 4

PMID 22300739

Citations 25

Authors

Sherri-Ann M Burnett-Bowie

Benjamin Z Leder

Maria P Henao

Chantel M Baldwin

Douglas L Hayden

Joel S Finkelstein

Affiliations

Soon will be listed here.

Abstract

Background And Objectives: Fibroblast growth factor 23 is a phosphate- and vitamin D-regulating hormone. The objective of this study was to determine the effect of ergocalciferol administration on fibroblast growth factor 23 levels in healthy vitamin D-deficient subjects.

Design, Setting, Participants, & Measurements: In this 12-week trial conducted in a clinical research center, 18- to 45-year-old subjects (n=90) with 25-hydroxyvitamin D levels ≤20 ng/ml (by chemiluminescent immunoassay) were randomized to weekly ergocalciferol treatment of 50,000 international units or placebo, while consuming a self-selected diet. Changes in fibroblast growth factor 23, 25-hydroxyvitamin D (by liquid chromatography/tandem mass spectroscopy), 1,25-dihydroxyvitamin D, parathyroid hormone, and serum phosphate were measured.

Results: Mean 25-hydroxyvitamin D (P<0.0001), 1,25-dihydroxyvitamin D (P=0.01), and fibroblast growth factor 23 (P=0.003) increased in the treatment versus placebo group. In the treatment group, 25-hydroxyvitamin D increased from 18 ± 7 to 40 ± 12 ng/ml at week 4 (P<0.0001) and remained stable at 43 ± 12 ng/ml at week 12 (P<0.0001); 1,25-dihydroxyvitamin D increased from 42 ± 17 to 52 ± 18 pg/ml at week 4 (P<0.001) and then remained stable, and fibroblast growth factor 23 increased from 43 ± 17 to 60 ± 33 pg/ml at week 8 (P=0.001) and 74 ± 42 pg/ml at week 12 (P<0.0001). Urinary phosphate excretion increased within the treatment group, but parathyroid hormone and serum phosphate were unchanged.

Conclusions: Ergocalciferol administration increases circulating fibroblast growth factor 23. When measuring fibroblast growth factor 23, concurrent 25-hydroxyvitamin D measurements should be obtained, because vitamin D deficiency may lower circulating fibroblast growth factor 23 levels.

Citing Articles

1,25-Dihydroxyvitamin D3 regulates furin-mediated FGF23 cleavage.

Xie H, Bastepe I, Zhou W, Ay B, Ceraj Z, Portales-Castillo I JCI Insight. 2023; 8(17).

PMID: 37681408 PMC: 10544208. DOI: 10.1172/jci.insight.168957.

Scientific opinion on the tolerable upper intake level for vitamin D, including the derivation of a conversion factor for calcidiol monohydrate.

Turck D, Bohn T, Castenmiller J, de Henauw S, Hirsch-Ernst K, Knutsen H EFSA J. 2023; 21(8):e08145.

PMID: 37560437 PMC: 10407748. DOI: 10.2903/j.efsa.2023.8145.

Effect of vitamin D supplementation on circulating fibroblast growth factor-23 concentration in adults with prediabetes.

Ceglia L, Pittas A, Dawson-Hughes B Aging Clin Exp Res. 2023; 35(3):525-530.

PMID: 36631721 DOI: 10.1007/s40520-022-02338-y.

Longitudinal Evolution of Markers of Mineral Metabolism in Patients With CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study.

Isakova T, Cai X, Lee J, Mehta R, Zhang X, Yang W Am J Kidney Dis. 2019; 75(2):235-244.

PMID: 31668375 PMC: 7012684. DOI: 10.1053/j.ajkd.2019.07.022.

Oral vitamin D supplementation increases serum fibroblast growth factor 23 concentration in vitamin D-deficient patients: a systematic review and meta-analysis.

Charoenngam N, Rujirachun P, Holick M, Ungprasert P Osteoporos Int. 2019; 30(11):2183-2193.

PMID: 31372708 DOI: 10.1007/s00198-019-05102-7.

References

Heikkinen A, Parviainen M, Tuppurainen M, Niskanen L, Komulainen M, Saarikoski S . Effects of postmenopausal hormone replacement therapy with and without vitamin D3 on circulating levels of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D. Calcif Tissue Int. 1998; 62(1):26-30. DOI: 10.1007/s002239900389. View

Bischoff H, Stahelin H, Dick W, Akos R, Knecht M, Salis C . Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial. J Bone Miner Res. 2003; 18(2):343-51. DOI: 10.1359/jbmr.2003.18.2.343. View

Herrmann M, Harwood T, Gaston-Parry O, Kouzios D, Wong T, Lih A . A new quantitative LC tandem mass spectrometry assay for serum 25-hydroxy vitamin D. Steroids. 2010; 75(13-14):1106-12. DOI: 10.1016/j.steroids.2010.07.006. View

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke H, Choukroun G . FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2011; 23(7):2017-25. DOI: 10.1007/s00198-011-1838-0. View

. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet. 2000; 26(3):345-8. DOI: 10.1038/81664. View

Holick M, Biancuzzo R, Chen T, Klein E, Young A, Bibuld D . Vitamin D2 is as effective as vitamin D3 in maintaining circulating concentrations of 25-hydroxyvitamin D. J Clin Endocrinol Metab. 2007; 93(3):677-81. PMC: 2266966. DOI: 10.1210/jc.2007-2308. View

Heaney R, Dowell S, Chen T, Holick M . Vitamin D and its major metabolites: serum levels after graded oral dosing in healthy men. Osteoporos Int. 1998; 8(3):222-30. DOI: 10.1007/s001980050058. View

Cockcroft D, GAULT M . Prediction of creatinine clearance from serum creatinine. Nephron. 1976; 16(1):31-41. DOI: 10.1159/000180580. View

10.

Gutierrez O, Wolf M, Taylor E . Fibroblast growth factor 23, cardiovascular disease risk factors, and phosphorus intake in the health professionals follow-up study. Clin J Am Soc Nephrol. 2011; 6(12):2871-8. PMC: 3255372. DOI: 10.2215/CJN.02740311. View

11.

Romagnoli E, Mascia M, Cipriani C, Fassino V, Mazzei F, DErasmo E . Short and long-term variations in serum calciotropic hormones after a single very large dose of ergocalciferol (vitamin D2) or cholecalciferol (vitamin D3) in the elderly. J Clin Endocrinol Metab. 2008; 93(8):3015-20. DOI: 10.1210/jc.2008-0350. View

12.

Kobayashi K, Imanishi Y, Miyauchi A, Onoda N, Kawata T, Tahara H . Regulation of plasma fibroblast growth factor 23 by calcium in primary hyperparathyroidism. Eur J Endocrinol. 2005; 154(1):93-9. DOI: 10.1530/eje.1.02053. View

13.

Antoniucci D, Yamashita T, Portale A . Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab. 2006; 91(8):3144-9. DOI: 10.1210/jc.2006-0021. View

14.

Uzum A, Salman S, Telci A, Boztepe H, Tanakol R, Alagol F . Effects of vitamin D replacement therapy on serum FGF23 concentrations in vitamin D-deficient women in short term. Eur J Endocrinol. 2010; 163(5):825-31. DOI: 10.1530/EJE-10-0591. View

15.

Ito M, Sakai Y, Furumoto M, Segawa H, Haito S, Yamanaka S . Vitamin D and phosphate regulate fibroblast growth factor-23 in K-562 cells. Am J Physiol Endocrinol Metab. 2005; 288(6):E1101-9. DOI: 10.1152/ajpendo.00502.2004. View

16.

Heaney R, Dowell M, Chen T, Holick M . Calcium absorptive effects of vitamin D and its major metabolites. J Clin Endocrinol Metab. 1997; 82(12):4111-6. DOI: 10.1210/jcem.82.12.4412. View

17.

Juppner H, Wolf M, Salusky I . FGF-23: More than a regulator of renal phosphate handling?. J Bone Miner Res. 2010; 25(10):2091-7. PMC: 3153315. DOI: 10.1002/jbmr.170. View

18.

Feng J, Ward L, Liu S, Lu Y, Xie Y, Yuan B . Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet. 2006; 38(11):1310-5. PMC: 1839871. DOI: 10.1038/ng1905. View

19.

Pfeifer M, Begerow B, Minne H, Nachtigall D, Hansen C . Effects of a short-term vitamin D(3) and calcium supplementation on blood pressure and parathyroid hormone levels in elderly women. J Clin Endocrinol Metab. 2001; 86(4):1633-7. DOI: 10.1210/jcem.86.4.7393. View

20.

Armas L, Hollis B, Heaney R . Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab. 2004; 89(11):5387-91. DOI: 10.1210/jc.2004-0360. View